EGFR activation limits the response of liver cancer to lenvatinib.

Animals Antineoplastic Agents / pharmacology Carcinoma, Hepatocellular / drug therapy Cell Line, Tumor Drug Resistance, Neoplasm ErbB Receptors / antagonists & inhibitors Female Gefitinib / pharmacology Humans Liver Neoplasms / drug therapy Male Mice Mice, Inbred BALB C Mice, Nude Phenylurea Compounds / pharmacology Quinolines / pharmacology Receptors, Fibroblast Growth Factor Signal Transduction Xenograft Model Antitumor Assays

Journal

Nature

ISSN: 1476-4687

Titre abrégé: Nature

Pays: England

ID NLM: 0410462

Informations de publication

Date de publication:
07 2021

Historique:

received: 08 05 2020

accepted: 21 06 2021

pubmed: 23 7 2021

medline: 27 1 2022

entrez: 22 7 2021

Statut: ppublish

Résumé

Hepatocellular carcinoma (HCC)-the most common form of liver cancer-is an aggressive malignancy with few effective treatment options

Identifiants

DOI: 10.1038/s41586-021-03741-7 PMID: 34290403

pubmed: 34290403

doi: 10.1038/s41586-021-03741-7

pii: 10.1038/s41586-021-03741-7

doi:

Substances chimiques

Antineoplastic Agents 0

Phenylurea Compounds 0

Quinolines 0

Receptors, Fibroblast Growth Factor 0

EGFR protein, human EC 2.7.10.1

ErbB Receptors EC 2.7.10.1

lenvatinib EE083865G2

Gefitinib S65743JHBS

Banques de données

ClinicalTrials.gov

['NCT04642547']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

730-734

Subventions

Organisme : European Research Council

Pays : International

Commentaires et corrections

Type : CommentIn

Informations de copyright

Références

Villanueva, A. Hepatocellular carcinoma. N. Engl. J. Med. 380, 1450–1462 (2019).

doi: 10.1056/NEJMra1713263

Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 1163–1173 (2018).

doi: 10.1016/S0140-6736(18)30207-1

Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).

doi: 10.3322/caac.21660

Zucman-Rossi, J., Villanueva, A., Nault, J.-C. & Llovet, J. M. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 149, 1226–1239 (2015).

doi: 10.1053/j.gastro.2015.05.061

Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).

doi: 10.1056/NEJMoa0708857

Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894–1905 (2020).

doi: 10.1056/NEJMoa1915745

Evers, B. et al. CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes. Nat. Biotechnol. 34, 631–633 (2016).

doi: 10.1038/nbt.3536

Zhu, A. X. et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 33, 559–566 (2015).

doi: 10.1200/JCO.2013.53.7746

Matsuki, M. et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 7, 2641–2653 (2018).

doi: 10.1002/cam4.1517

Wagle, M.-C. et al. A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. NPJ Precis. Oncol. 2, 7 (2018).

doi: 10.1038/s41698-018-0051-4

Pirker, R. et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 13, 33–42 (2012).

doi: 10.1016/S1470-2045(11)70318-7

Kimura, T. et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci. 109, 3993–4002 (2018).

doi: 10.1111/cas.13806

Li, E., Lin, L., Chen, C. W. & Ou, D. L. Mouse models for immunotherapy in hepatocellular carcinoma. Cancers (Basel) 11, 1800 (2019).

doi: 10.3390/cancers11111800

Keng, V. W. et al. A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat. Biotechnol. 27, 264–274 (2009).

doi: 10.1038/nbt.1526

He, H. et al. Platelet-derived growth factor requires epidermal growth factor receptor to activate p21-activated kinase family kinases. J. Biol. Chem. 276, 26741–26744 (2001).

doi: 10.1074/jbc.C100229200

Lee, S.-W. et al. EGFR–Pak signaling selectively regulates glutamine deprivation-induced macropinocytosis. Dev. Cell 50, 381–392 (2019).

doi: 10.1016/j.devcel.2019.05.043

Vaseva, A. V. et al. KRAS suppression-induced degradation of MYC is antagonized by a MEK5–ERK5 compensatory mechanism. Cancer Cell 34, 807–822 (2018).

doi: 10.1016/j.ccell.2018.10.001

Duncan, J. S. et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307–321 (2012).

doi: 10.1016/j.cell.2012.02.053

Lito, P. et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 22, 668–682 (2012).

doi: 10.1016/j.ccr.2012.10.009

Kosoff, R. E. et al. Pak2 restrains endomitosis during megakaryopoiesis and alters cytoskeleton organization. Blood 125, 2995–3005 (2015).

doi: 10.1182/blood-2014-10-604504

Kobayashi, S. et al. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res. 66, 11389–11398 (2006).

doi: 10.1158/0008-5472.CAN-06-2318

Philip, P. A. et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J. Clin. Oncol. 23, 6657–6663 (2005).

doi: 10.1200/JCO.2005.14.696

Chan, S. L. et al. New utility of an old marker: serial α-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J. Clin. Oncol. 27, 446–452 (2009).

doi: 10.1200/JCO.2008.18.8151

Llovet, J. M. & Lencioni, R. mRECIST for HCC: performance and novel refinements. J. Hepatol. 72, 288–306 (2020).

doi: 10.1016/j.jhep.2019.09.026

Ding, X. et al. Genomic and epigenomic features of primary and recurrent hepatocellular carcinomas. Gastroenterology 157, 1630–1645 (2019).

doi: 10.1053/j.gastro.2019.09.005

Cremolini, C. et al. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann. Oncol. 26, 1188–1194 (2015).

doi: 10.1093/annonc/mdv112

Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).

doi: 10.1186/s13059-014-0550-8

Jin, H. et al. Regulator of calcineurin 1 gene isoform 4, down-regulated in hepatocellular carcinoma, prevents proliferation, migration, and invasive activity of cancer cells and metastasis of orthotopic tumors by inhibiting nuclear translocation of NFAT1. Gastroenterology 153, 799–811 (2017).

doi: 10.1053/j.gastro.2017.05.045

Mazières, J. et al. Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study. Lung Cancer 82, 231–237 (2013).

doi: 10.1016/j.lungcan.2013.07.016

Sun, C. et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508, 118–122 (2014).

doi: 10.1038/nature13121

Wang, L. et al. High-throughput functional genetic and compound screens identify targets for senescence induction in cancer. Cell Rep. 21, 773–783 (2017).

doi: 10.1016/j.celrep.2017.09.085

Schuhmacher, M. et al. The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res. 29, 397–406 (2001).

doi: 10.1093/nar/29.2.397

Wang, C. et al. Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature 574, 268–272 (2019).

doi: 10.1038/s41586-019-1607-3

World Medical Association. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull. World Health Organ. 79, 373–374 (2001).

pmcid: 2566407